SLNO - NASDAQ
Soleno Therapeutics, Inc.
$53.01
+0.038%Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
At a Glance
Live SnapshotSoleno Therapeutics, Inc. Management Team
Dr. Anish Bhatnagar M.D.
Chairman, President, Chief Executive Officer & Chief Operating Officer
Compensation
$1,046,200
Ms. Meredith Manning M.B.A.
Chief Commercial Officer
Compensation
$605,161
Mr. James H. MacKaness
Chief Financial Officer & Compliance Officer
Compensation
$656,200
Mr. Jesse Schumaker
General Counsel
Dr. Michael Huang M.D.
Senior Vice President of Clinical Development
Dr. Neil M. Cowen M.B.A., Ph.D.
Senior Vice President of Drug Development
Ms. Kristen Yen M.S.
Senior Vice President of Global Clinical Operations and Patient Advocacy
Compensation
$317,190
Dr. Mitchell Nagao M.B.A., Pharm.D.
Senior Vice President of Medical Affairs
Ms. Lauren Budesheim
Senior Vice President of People
Ms. Patricia C. Hirano M.P.H.
Senior Vice President of Regulatory Affairs
Compensation
$515,813
Ms. Lauren Budesheim
Vice President of People
Soleno Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $485K worth of SLNO shares, with no buying activity reported.
3 Months
0
0.00
4.9K
146.10K
-146K
-$146K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
4.1K
339.38K
-339K
-$339K
Top Buyers
No buying activity
Top Sellers
Hirano Patricia C
Officer: See Remarks
$339K
Manning Meredith
Officer: Chief Commercial Officer
$146K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $485K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
SEC Filings
SLNO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 22, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 22, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 14, 2023 | May 25, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 01, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 21, 2021 | June 01, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | October 19, 2020 | November 10, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | April 20, 2020 | May 18, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | June 10, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | June 11, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 13, 2017 | May 08, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.